Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from AstraZeneca and Tesaro, Inc.
Release Date: October 31, 2018
Expiration Date: October 31, 2019
Media: Internet - based
This activity, Oncology Consultations® in Ovarian Cancer: Differentiating Among Clinical Trial Designs to Match PARP to Patient, developed in the Physicians’ Education Resource, LLC, (PER®) established Oncology Consultations® legacy format, focuses on the landscape of clinical trial design and key data guiding the use of PARP inhibitors in ovarian cancer. This presentation features Dr. Susana Campos and Dr. Shannon Westin reviewing the study designs that led to current and emerging indications for the use of PARP inhibitors and discussing ongoing clinical trials in this field. Throughout this activity, they provide their expert viewpoints on the role of PARP inhibitors in ovarian cancer, including placing cutting-edge data into the context of case-based discussion to guide the use of PARP inhibitors for treatment of your patients.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Tesaro, Inc.
Instructions for This Activity and Receiving Credit
This activity is directed toward medical oncologists, gynecologic oncologists, radiation oncologists, surgical oncologists, and other health care professionals who manage and treat patients with ovarian cancer.
At the conclusion of this activity, you should be better prepared to:
Susana Campos, MD
Assistant Professor of Medicine
Harvard Medical School
Dana Farber Cancer Institute
Disclosure: Consultant: Clovis
Shannon N. Westin, MD, MPH, FACOG
Department of Gynecologic Oncology and Reproductive Medicine
Director, Early Drug Development
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/Research Support: AstraZeneca, Genentech, Clovis, Tesaro, Bayer, Novartis, Cotinga Pharmaceuticals; Consultant: AstraZeneca, Roche/Genentech, Clovis, Tesaro, Merck, Ovation, Medivation, OncLive, Medscape
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
March 7, 2019 - March 10, 2019
March 8, 2019
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Acute Myeloid Leukemia
Mar 30, 2019
Mar 30, 2019
Mar 30, 2019